文献速递临床试验与 GCP

基于穴位配伍理论的针刺治疗肠易激综合征疗效:多中心随机对照试验研究方案

Efficacy of acupuncture based on acupoint combination theory for irritable bowel syndrome: a study protocol for a multicenter randomized controlled trial.
PubMed 文献 · Trials · 2021-10-19

本研究为多中心随机对照试验方案,计划纳入204例符合Rome IV标准的肠易激综合征患者,按1:1:1随机分为针刺A组、针刺B组和对照组,每组接受4周共12次针刺治疗并随访4周。主要结局为IBS症状严重度量表评分,次要结局包括大便性状、工作与社会适应、生活质量及焦虑抑郁量表评分,旨在评估针刺疗效与安全性并探索最优穴位组合。

要点

  • 多中心随机对照试验比较不同穴位组合针刺与常规治疗对IBS的疗效。
  • 主要结局为IBS-SSS评分,次要结局涵盖大便性状、生活质量及情绪量表。
  • 计划纳入204例Rome IV标准IBS患者,1:1:1随机分组,治疗4周随访4周。

核心结论

  • 该研究方案旨在评估针刺治疗IBS的疗效与安全性,并探索推荐的最优穴位组合及多穴协同效应。

研究设计与样本

  • 多中心随机对照试验方案,计划纳入204例符合Rome IV标准的IBS患者。
  • 采用中央网络随机系统按1:1:1分层随机分为针刺A组、针刺B组和对照组。
  • 每组接受4周共12次针刺治疗,随后随访4周。

关键数值与推荐

  • 对照组预设穴位包括双侧天枢(ST25)、上巨虚(ST37)、内关(PC6)和足三里(ST36)。
  • 针刺A组预设穴位包括双侧天枢(ST25)、上巨虚(ST37)和内关(PC6)。
  • 针刺B组预设穴位包括双侧天枢(ST25)、上巨虚(ST37)和足三里(ST36)。
  • 主要结局为IBS症状严重度量表(IBS-SSS)评分。
  • 次要结局包括Bristol大便性状量表(BSFS)、工作与社会适应评分(WSAS)、IBS生活质量(IBS-QOL)、焦虑自评量表(SAS)和抑郁自评量表(SDS)评分。

临床怎么用

  • 该方案尚处于研究阶段,结果发表前不能作为临床推荐依据。

局限性

  • 本文为研究方案,尚未报告疗效与安全性结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by abdominal pain, diarrhea or constipation, and changes in defecation patterns. No organic disease is found to explain these symptoms by routine clinical examination. This study aims to investigate the efficacy and safety of acupuncture therapy for IBS patients compared with those of conventional treatments. We also aim to identify the optimal acupoint combination recommended for IBS and to clarify the clinical advantage of the "multiacupoint co-effect and synergistic effect." METHODS AND ANALYSIS: A total of 204 eligible patients who meet the Rome IV criteria for IBS will be randomly stratified into acupuncture group A, acupuncture group B, or the control group in a 1:1:1 ratio with a central web-based randomization system. The prespecified acupoints used in the control group will include bilateral Tianshu (ST25), Shangjuxu (ST37), Neiguan (PC6), and Zusanli (ST36). The prespecified acupoints used in experimental group A will include bilateral Tianshu (ST25), Shangjuxu (ST37), and Neiguan (PC6). The prespecified acupoints used in experimental group B will include bilateral Tianshu (ST25), Shangjuxu (ST37), and Zusanli (ST36). Each patient will receive 12 acupuncture treatments over 4 weeks and will be followed up for 4 weeks. The primary outcome is the IBS-Symptom Severity Scale (IBS-SSS) score. The secondary outcomes include the Bristol Stool Form Scale (BSFS), Work and Social Adjustment Score (WSAS), IBS-Quality of Life (IBS-QOL), Self-Rating Anxiety Scale (SAS), and Self-Rating Depression Scale (SDS) scores. Both the primary outcome and the secondary outcome measures will be collected at baseline, at 2 and 4 weeks during the intervention, and at 6 weeks and 8 weeks after the intervention. ETHICS AND DISSEMINATION: The entire project has been approved by the ethics committee of the Beijing University of Chinese Medicine (2020BZYLL0903). DISCUSSION: This is a multicenter randomized controlled trial for IBS in China. The findings may shed light on the efficacy of acupuncture as an alternative to conventional IBS treatment. The results of the trial will be disseminated in peer-reviewed publications. TRIAL REGISTRATION: Chinese Clinical Trials Register ChiCTR2000041215 . First registered on 12 December 2020. http://www.chictr.org.cn/ .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sun JW, Sun ML, Li D, et al. Efficacy of acupuncture based on acupoint combination theory for irritable bowel syndrome: a study protocol for a multicenter randomized controlled trial. Trials. 2021. PMID: 34666815. doi:10.1186/s13063-021-05432-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。